
Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System

K. Mackie

University of Washington, Box 356540, Seattle WA, 98195-6540, USA
kmackie@u.washington.edu

1	Introduction	300
1.1	Background	300
1.2	Autoradiography	301
1.3	In Situ Hybridization	301
1.4	Immunocytochemistry	303
1.5	Functional Studies	305
2	CB₁ Expression in Specific CNS Regions	305
2.1	Olfactory Areas	305
2.2	Neocortex	306
2.3	Hippocampal Formation	308
2.3.1	Hippocampus	308
2.3.2	Dentate Gyrus	310
2.4	Amygdala	310
2.5	Subcortical CB ₁ Receptors	310
2.5.1	Basal Forebrain	310
2.5.2	Basal Ganglia	311
2.5.3	Nucleus Accumbens	313
2.5.4	Thalamus	313
2.5.5	Hypothalamus	313
2.6	Midbrain	313
2.6.1	Substantia Nigra	313
2.6.2	Ventral Tegmentum	314
2.6.3	Periaqueductal Gray	315
2.7	Brainstem	315
2.8	Cerebellum	316
2.9	Spinal Cord	317
3	Peripheral Nervous System	318
3.1	Peripheral Nerves	318
3.2	Enteric Nervous System	318
3.3	Pelvic Viscera	319
4	Summary	319
	References	320

Abstract CB₁ cannabinoid receptors appear to mediate most, if not all of the psychoactive effects of delta-9-tetrahydrocannabinol and related compounds. This G

protein-coupled receptor has a characteristic distribution in the nervous system: It is particularly enriched in cortex, hippocampus, amygdala, basal ganglia outflow tracts, and cerebellum—a distribution that corresponds to the most prominent behavioral effects of cannabis. In addition, this distribution helps to predict neurological and psychological maladies for which manipulation of the endocannabinoid system might be beneficial. CB₁ receptors are primarily expressed on neurons, where most of the receptors are found on axons and synaptic terminals, emphasizing the important role of this receptor in modulating neurotransmission at specific synapses. While our knowledge of CB₁ localization in the nervous system has advanced tremendously over the past 15 years, there is still more to learn. Particularly pressing is the need for (1) detailed anatomical studies of brain regions important in the therapeutic actions of drugs that modify the endocannabinoid system and (2) the determination of the localization of the enzymes that synthesize, degrade, and transport the endocannabinoids.

Keywords Immunocytochemistry · In situ hybridization · Autoradiography · Cholecystokinin · Synapse

1

Introduction

1.1

Background

The CB₁ cannabinoid receptor is the major mediator of the psychoactive effects of cannabis and its derivatives. In addition, this G protein-coupled receptor transduces many of the effects of the endogenous cannabinoids. Understanding the distribution of CB₁ receptors has proved helpful to both predict and understand the effects of cannabinoids. For example, the high CB₁ receptor levels found in cortex, basal ganglia, and cerebellum coincide with the prominent effects cannabinoids have on functions subserved by these brain regions. By comparison, the low levels present in the medullary nuclei responsible for regulating respiration are consistent with the modest effects cannabinoids have on respiratory drive. Furthermore, the strong presynaptic localization of the receptor found in ultrastructural studies underscores its major role as a modulator of neurotransmitter release.

The distribution of cannabinoid receptors has been extensively mapped by quantitative autoradiography, in situ hybridization, and immunocytochemistry. Each of these techniques has its strengths and weaknesses. Properly calibrated, quantitative autoradiography provides the best measure of absolute receptor density. Nonetheless, its spatial resolution is limited and specificity depends on the ligand used. In situ hybridization identifies the cells synthesizing CB₁ mRNA. However, mRNA levels and protein levels may not necessarily correlate. Immunocytochemistry provides outstanding spatial resolution; however, fixation artifacts and unanticipated antibody crossreactivity must be assiduously avoided. For the most

part, the results obtained from these three approaches have provided complementary and logically consistent results. In addition to these anatomical approaches, it is possible to obtain a measure of CB₁ receptor function by guanosine triphosphate (GTP) γ S binding, giving spatial resolution similar to quantitative autoradiography. Finally, the results of experiments using regionally or neuron specific CB₁ knockout mice can give additional insight into receptor localization.

1.2

Autoradiography

Miles Herkenham performed the first CB₁ receptor distribution studies using autoradiography with the tritiated CB₁ agonist, CP55,940. Examples of his results from human brain are shown in Fig. 1. A striking feature of the autoradiographic studies was the extraordinarily high levels of CB₁ receptors found in substantia nigra, globus pallidus, hippocampus, cerebellum, and cortex. The levels of CB₁ receptors found in these brain regions in the rat approached 6 pmole/mg (Herkenham et al. 1991). To give a sense of the magnitude of CB₁ receptor expression, CB₁ receptors are tenfold denser than D₂ receptors in the basal ganglia and have a density similar to cortical ionotropic glutamate receptors. The specificity of these results was verified by Virginia Seybold and her colleagues, who performed a systematic autoradiographic study of rat brain using tritiated WIN55,212-2, a structurally distinct CB₁ agonist (Jansen et al. 1992). These thorough studies in rodents have been complemented by autoradiographic studies in human brain (Glass et al. 1997; Mato et al. 2003). The results of the human and rodent studies are qualitatively similar once the evolutionary changes associated with the development of the human brain are considered.

1.3

In Situ Hybridization

Cloning the CB₁ receptor (Matsuda et al. 1990) made it possible to identify CB₁ synthesizing cells by in situ hybridization (Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993). Correlating the results of the autoradiographic and in situ hybridization studies reveals several common themes of the CB₁ system. The first was that in some brain regions, particularly forebrain (for example, cortex, amygdala, and hippocampus), CB₁ receptors are expressed at very high levels in a very restricted set of neurons. These neurons then project widely, resulting in a dense network of CB₁-positive axons. The second was that CB₁ receptors were primarily found on axons and terminals. For example, high levels of CB₁ are present in the striatonigral pathway and substantia nigra, yet nigral neurons express no CB₁ mRNA. These findings strongly suggest CB₁ receptors are synthesized in the striatal projection neurons (medium spiny neurons—which contain moderate levels of CB₁ mRNA) and are trafficked to their axons. The axonal and terminal localization of CB₁ receptors, coupled with the observation that CB₁ receptors inhibit presynaptic calcium channels, implied that a major function of CB₁ receptors would be to




Fig. 1. CB₁ expression in human brain. CB₁ receptors were detected by quantitative autoradiography using tritiated CP55,940. Strikingly high levels are found in the substantia nigra pars reticulata (SNR) and the internal segment of the globus pallidus (GPi). Moderate levels are present in the caudate, putamen, the external segment of the globus pallidus (GPe), amygdala, and cortex. Lesser levels are present in hypothalamus, and very low expression is apparent in most areas of the thalamus. The laminar nature of CB₁ expression is apparent in the most rostral parts of the cortex. Scale bar = 1 cm. (Original figure provided by Miles Herkenham)

inhibit neurotransmitter release. The third theme was that in a few brain regions (for example, anterior olfactory nucleus, caudate nucleus and cerebellum) CB₁ receptors are uniformly expressed at moderate levels on a single class of neurons.

1.4

Immunocytochemistry

Elucidation of the primary sequence of the CB₁ receptor allowed for production of numerous CB₁ receptor antibodies. There have been two thorough immunocytochemical mapping studies in rodent brain (Tsou et al. 1998a; Egertová and Elphick 2000) and one in spinal cord (Farquhar-Smith et al. 2000). These generally support the results from the autoradiographic studies, with some differences in relative intensity of staining. These variations may be due to differences in antibody access to specific epitopes, variable post-translational modification of an epitope (e.g., phosphorylation), or fixation conditions. There is little evidence for alternative splicing in the coding region of rodent CB₁ receptors (Matsuda 1997; Lutz 2002), despite the report of alternatively splicing of the human CB₁ receptor (Shire et al. 1995; Matsuda 1997; Lutz 2002); so alternative splicing is less likely to explain the reported differences.

The immunocytochemical studies have led to additional insights into cannabinoid action. The first is that rigorous electron microscopic studies in the hippocampus demonstrated that in this region CB₁ is undetectable on somatic cell membranes and dendrites, yet is very highly expressed in axon terminals and preterminal segments (Hajos et al. 2000; Katona et al. 2000, 2001). An example of this is shown in Fig. 2, with the labeling of four consecutive ultrathin sections of a cortical axodendritic synapse. The second is that double-label immunostaining experiments demonstrated that in forebrain there is a striking correlation between cholecystokinin (CCK) and CB₁ receptor expression (Katona et al. 1999, 2001; Tsou et al. 1999). These findings have been confirmed and extended with double-label *in situ* hybridization studies (Marsicano and Lutz 1999). Thus, the cells expressing the highest levels of CB₁ receptors in forebrain are γ -aminobutyric acid (GABA)ergic, CCK-positive interneurons. Although inhibition of GABA release is measured in the *in vitro* electrophysiological studies, activation of CB₁ receptors *in vivo* will attenuate both inhibitory transmission (generally fast, mediated by GABA A receptors) (Wilson et al. 2001) as well as the slow, excitatory actions mediated by CCK receptors (Beinfeld and Connolly 2001). Thus, the localization of CB₁ receptors on CCK-containing neurons suggests that CB₁ receptors are well positioned to modulate complex network behaviors (Freund 2003).

Once antibodies to the anandamide-degrading enzyme, namely fatty acid amide hydrolase (FAAH), became available, it was apparent that in many regions FAAH and CB₁ expression is reciprocal in nature (Egertová et al. 1998, 2003; Tsou et al. 1998b). For example, FAAH, but not CB₁ is highly expressed in the somata and proximal dendrites of hippocampal pyramidal cells and cerebellar Purkinje neurons. These neurons are, in turn, densely innervated by CB₁-positive fibers. Thus, it has been proposed that anandamide, despite its possible presynaptic site




Fig. 2A–C. CB₁ expression in serial sections of a γ -aminobutyric acidergic (GABAergic) terminal synapsing onto an apical dendrite in cortex. CB₁ receptors (arrowheads) were detected with an antibody directed against the C terminus of rat CB₁ using pre-embedding immunogold with silver enhancement. The boutons are forming symmetric synapses (arrows), characteristic of GABAergic axon terminals, onto the apical dendrite of a cortical pyramidal cell. Scale bar = 0.5 μ m. (Original photomicrograph provided by Tamas Freund and Agnes Bodor)




Fig. 3A–C. Reciprocal expression of CB₁ and FAAH in mouse hippocampus. FAAH was detected using an antibody raised against the last 200 residues of FAAH, CB₁ receptors were detected by an antibody directed against its C terminus, and neuronal nuclear antigen (NeuN) was detected using a mouse monoclonal antibody from Chemicon. FAAH is expressed uniformly by pyramidal neurons (Pyr) including the apical dendrites. FAAH is also expressed in interneurons (open and filled arrows). CB₁ receptors are present in axons investing the pyramidal cell layer and also some interneuron cell bodies (filled arrows), but not in others (open arrow). Staining of neurons by NeuN identifies neuronal nuclei in the field. Scale bar = 18 μ m. (Figure provided by Tibor Harkany)

of action, is synthesized and degraded in the postsynaptic neuron. An example of this reciprocal localization in the CA1 region of mouse hippocampus is shown in Fig. 3. The situation for monoacylglycerol (MAG) lipase, the major 2-arachidonoyl glycerol-degrading enzyme, is still being clarified. However, a recent paper suggests that MAG lipase, in contrast to FAAH is predominately localized presynaptically (Gulyas et al. 2004). As the majority of CB₁ receptors are presynaptic, location of MAG lipase near these receptors would mean the endogenous cannabinoid 2-AG would be metabolized at its likely site of action, rather than having to diffuse back across the synapse. Thorough studies on the anatomical distribution of the endocannabinoid-synthesizing enzymes, diacylglycerol lipase (Bisogno et al. 2003) and the *N*-acyl phosphatidylethanolamine-preferring phospholipase D (Okamoto et al. 2004), remain to be done.

1.5

Functional Studies

Functional studies have provided another dimension in cannabinoid receptor localization. The most pertinent studies for this chapter are GTP γ S studies and results inferred from studies with CB₁ knockout mice. The chapter by Lindsey et al. (this volume) will consider advances in positron emission tomography (PET), single-photon emission computed tomography (SPECT) and 2-deoxy-glucose imaging of CB₁ receptors and their activation. GTP γ S studies provide a measure of regional CB₁ receptor activation of G proteins with a spatial resolution similar to other autoradiographic studies. Informative results from these studies include the observation that CB₁ receptors are relatively inefficient activators of G protein (for example, sevenfold less efficient than μ - or δ -opioid receptors) and that activation of G proteins by CB₁ receptors desensitizes strongly with chronic tetrahydrocannabinol (THC) treatment (Sim et al. 1996a,b). As mentioned below, the region-specific CB₁ knockout mice experiments support the contention that some CB₁ receptors may be expressed on hippocampal pyramidal neurons.

2

CB₁ Expression in Specific CNS Regions

2.1

Olfactory Areas

The highest levels of CB₁ receptors in olfactory bulb are in the inner granule cell layer, followed by the inner plexiform layer. The external plexiform layer, the mitral cell (glomerular) layer, and the accessory olfactory bulb have few CB₁ receptors (Herkenham et al. 1991; Tsou et al. 1998a; Egertová and Elphick 2000). The anterior olfactory nucleus and anterior commissure, which connects the olfactory bulbs, both contain high levels of CB₁ receptor. In contrast to neighboring regions, CB₁ receptors are expressed uniformly by most neurons in the anterior olfactory




Fig. 4. Laminar CB₁ expression in cortex of three mammals. CB₁ receptors were detected with an antibody directed against the C terminus of rat CB₁. Particularly high levels of CB₁ are found in lamina layers II, upper III (L2/3), IV (L4), and VI (L6). Scale bar = 250 μ m. (Figure provided by Tibor Harkany)

nucleus (Herkenham et al. 1991; Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993; Tsou et al. 1998a; Marsicano and Lutz 1999; Egertová and Elphick 2000). CB₁ receptors are also found in the supporting cells of the olfactory epithelium as well as axon bundles of the lamina propria (M. Caillol, personal communication).

2.2

Neocortex

CB₁ receptors are densely expressed in all regions of the cortex (Herkenham et al. 1991; Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993; Glass et al. 1997; Tsou et al. 1998a; Egertová and Elphick 2000). The variation in CB₁ expression across cortical regions has been examined most extensively in human brain using receptor autoradiography. Here there is variation between regions, with higher




Fig. 5A–C. CB₁ expression on GABAergic terminals in rat somatosensory cortex. CB₁ receptors (arrowheads) were detected with an antibody directed against the C terminus of rat CB₁ using pre-embedding immunogold with silver enhancement. The boutons are forming symmetric synapses (arrows), characteristic of cortical GABAergic axon terminals. CB₁-positive terminals form synapses with pyramidal cell bodies (**A**), main apical dendrites (**B**), and fine-caliber dendrite branches (**C**). Scale bar = 0.5 μ m. (Original photomicrograph provided by Tamas Freund and Agnes Bodor)

levels found in cingulate gyrus, frontal cortex, and secondary somatosensory and motor cortex. Lesser levels are found in primary somatosensory and motor cortex (Glass et al. 1997). The laminar nature of CB₁ expression within the neocortex is striking. The relative levels of expression between regions vary (Glass et al. 1997). However, as an example, in rat somatosensory cortex, CB₁ levels are relatively higher in layers II, upper III, IV, and VI. In contrast, CB₁ receptor expression is relatively less in deeper layer III and layer V (Freund et al. 2003). Layer I appears almost devoid of CB₁ receptors. Examples of CB₁ immunoreactivity in mouse, rat, and mouse lemur cortex are shown in Fig. 4. While the general laminar pattern between species is preserved, the amount of CB₁ expression appears to increase, particularly in layers III and V in the primate. Ultrastructural studies reveal that in cortex, CB₁-positive terminals synapse onto pyramidal cell bodies, apical dendrites, and smaller caliber branches (Fig. 5).

In neocortex, almost all neurons expressing CB₁ at high or moderate levels are likely to be inhibitory due to the tight correlation between GAD65 and CB₁ mRNA expression (Marsicano and Lutz 1999). However, there appear to be CB₁-mediated actions on glutamatergic transmission in cortex (Sjostrom et al. 2003). The localization and nature of these cannabinoid receptors remain to be identified. As in most other forebrain areas, the majority of strongly CB₁-positive axons in the cortex appear to arise from CCK-expressing interneurons (Marsicano and Lutz 1999). However, among cortical neurons, those expressing lower levels of CB₁ receptors represent a more heterogeneous population, with 20% of the CB₁-positive cells not expressing detectable levels of CCK mRNA (Marsicano and Lutz




Fig. 6A, B. Co-localization of CCK with CB₁ in neocortex. **A** Expression of CCK in a cortical interneuron (arrow) and CCK-positive processes (arrowheads). **B** CB₁ is widely expressed in cortical axons. CCK-positive processes are often CB₁ positive as well (arrowheads). Scale bar = 25 μm. (Figure provided by Tibor Harkany)

1999). An example of this for layer II/III cortex is shown in Fig. 6. Here, a strongly CB₁-expressing neuron co-localizes with CCK immunoreactivity, and most CCK-containing fibers also are immunopositive for CB₁. However, there are also many CB₁-positive fibers that do not appear to contain CCK.

2.3

Hippocampal Formation

2.3.1

Hippocampus

The hippocampus expresses high levels of cannabinoid receptors. Because of the cognitive effects of cannabinoids, this brain region has received much attention as a site of action of endogenous and exogenous cannabinoids. The first autoradiographic studies found very high levels of CB₁ receptors in all subfields of the hippocampus as well as the dentate gyrus (Herkenham et al. 1991; Jansen et al. 1992). In situ hybridization studies revealed that most of this CB₁ receptor expression arose from a restricted subset of interneurons (Matsuda et al. 1990, 1993; Mailleux and Vanderhaeghen 1992). Immunocytochemical studies identified a dense plexus of CB₁-containing axon terminals surrounding the pyramidal cell layer (perisomatic labeling), consistent with CB₁ receptor expression on basket cell axons (Tsou et al. 1998a, 1999; Katona et al. 1999; Egertová and Elphick 2000). This is illustrated in Figs. 3 and 7.

Basket cells can be conveniently separated into two groups distinguished by CCK or parvalbumin expression (Freund and Buzsaki 1996; Freund 2003). Double-label immunocytochemistry has shown that high levels of CB₁ receptor expression are restricted to the CCK-expressing interneurons (Katona et al. 1999; Tsou et al. 1999). Given that the CCK-expressing interneurons may be involved in the more subjective (emotional and motivational) aspects of information processing, it is likely that endocannabinoids are involved in the normal function of these circuits, and exogenous cannabinoids may serve to disrupt them in some fashion. This




Fig. 7A, B. CB₁ expression in rat hippocampal formation. **A** CB₁ cannabinoid receptors were detected with an antibody raised against the C terminus of rat CB₁. Receptor levels are particularly high in the pyramidal cell layer (Py), the molecular layer (Mol) of the dentate gyrus (DG), and at the base of the granule cell layer (GrDG) of the dentate gyrus. Lesser levels are found in the stratum oriens (Or), stratum radiatum (Rad), stratum lucidum (SLu), and the polymorphic layer of the dentate gyrus (PoDG). CA1, field CA1 of the hippocampus; CA3, field CA3 of the hippocampus. **B** CB₁-positive fibers surround the somata of pyramidal cells (Py) in CA1. Numerous varicosities, corresponding to terminals, are apparent. CB₁ receptors are also seen on axon fibers, although at lower levels, in stratum oriens (Or) and stratum radiatum (Rad). For both images, scale bar = 100 μ m. (Original photomicrograph provided by Marja Van Sickle and Keith Sharkey)

pattern of selective interneuron and axonal CB₁ receptor expression is preserved at all stages of postnatal development in the rat (Morozov and Freund 2003).

Tight functional separation of GABAergic input onto CA1 pyramidal cells has also been demonstrated in an elegant electrophysiological study where only large, fast GABAergic inhibitory postsynaptic currents (IPSCs) mediated by inhibitory terminals expressing N-type [(Cav1.2); but not P-type (Cav1.1)] calcium channels were subject to depolarization-induced suppression of inhibition (Wilson et al. 2001). These electrophysiological results are satisfyingly consistent with the anatomical localization of the CB₁ receptor on perisomatic GABAergic terminals.

The expression of CB₁ receptors on principal cells of the hippocampus is a source of some controversy (as reviewed by Freund et al. 2003). On one hand, careful electron microscopic immunocytochemical studies with specific and sensitive CB₁ receptor antibodies have consistently failed to find CB₁ receptor expression in pyramidal cells (Katona et al. 1999, 2000; Hajos et al. 2000; Chen et al. 2003). On the other hand, in situ hybridization studies consistently show low levels of CB₁ mRNA in the stratum pyramidale (Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993; Marsicano and Lutz 1999). Complicating interpretation of these studies are the observations that several drugs acting at CB₁ receptors (for example, WIN55,212-2 and SR141716) also inhibit glutamate release from pyramidal neurons in a CB₁ receptor-independent fashion [that is, they inhibit release in CB₁ knockout mice (Hajos et al. 2001; Hajos and Freund 2002)]. The electrophysiological and in situ data could conceivably be reconciled by crossreactivity of the in situ probes with a receptor closely related to the CB₁ receptor. However, this does not seem to be the case, as targeted deletion of CB₁ receptors from hippocampal pyramidal neurons (sparing CB₁ receptors in the interneurons) eliminates

cannabinoid-mediated protection in a kainate neurotoxicity model (Marsicano et al. 2003). Although this issue is not yet resolved, a parsimonious explanation of experimental results thus far is that hippocampal pyramidal neurons may express CB₁ receptors, albeit at far lower levels than the CCK-containing basket cells.

2.3.2

Dentate Gyrus

As in the hippocampus, CB₁ receptors in dentate gyrus are primarily found in CCK-containing basket cells—parvalbumin-positive basket cells and the granule cells do not express CB₁ (Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993; Katona et al. 1999; Marsicano and Lutz 1999; Tsou et al. 1999). This results in high levels of CB₁ receptors in the inner third of the molecular layer and at the base of the granule cell layer in the dentate gyrus (Fig. 7). While it has not been studied anatomically, functional studies suggest the glutamatergic terminals of the perforant path may express CB₁ receptors (Kirby et al. 1995).

2.4

Amygdala

CB₁ receptor distribution in the amygdala is markedly heterogeneous (Katona et al. 2001; McDonald and Mascagni 2001). High levels are found in the basolateral complex (comprising the lateral, basal, and accessory basal nucleus), nucleus of the lateral olfactory tract, the periamygdaloid cortex, and amygdalohippocampal areas. In contrast, CB₁ receptors are sparsely expressed in the medial, central, and intercalated nuclei (Fig. 1). As in other regions of the forebrain, CB₁ receptors are primarily expressed on large, GABAergic, CCK-containing axon terminals (Katona et al. 2001; McDonald and Mascagni 2001). Activation of these CB₁ receptors by cannabinoids decreases GABA release from these terminals, which may disinhibit the basolateral glutamatergic pyramidal cells (Katona et al. 2001). As in other forebrain regions, there is also a relatively high concordance between CB₁ and serotonin-3 (5-HT₃) receptor expression in amygdala (Morales et al. 2004). Compelling evidence suggests that endocannabinoids play a role in modulating fear conditioning at the level of the amygdala (Marsicano et al. 2002), and amygdaloid CB₁ receptors may play a role in the panic states occasionally seen following consumption of prodigious quantities of cannabis.

2.5

Subcortical CB₁ Receptors

2.5.1

Basal Forebrain

Moderate levels of CB₁ receptors are present in the basal forebrain. Autoradiographic studies found CB₁ in the medial and lateral septum and the intermediate

nucleus of the lateral septum (Herkenham et al. 1991). CB₁ mRNA is present at moderate levels in many cells of the medial septum and the nucleus of the diagonal band (Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993). A recent immunocytochemical study in mouse revealed that the tenia tecta, ventral pallidum, and substantia innominata all contained a dense network of CB₁-positive fibers. In contrast, a fine meshwork of CB₁ receptor-containing fibers was present in the medial septum, diagonal bands, and nucleus basalis (Harkany et al. 2003). No CB₁ immunoreactivity was detected in basal forebrain cholinergic cells; instead these cells contained high levels of FAAH (Harkany et al. 2003). These results are in contrast to a report in monkey, which found CB₁ expression in cholinergic forebrain neurons (Lu et al. 1999). This discrepancy may be due to a difference between species or methodologies.

2.5.2

Basal Ganglia

The subcortical structures with the highest level of CB₁ receptor expression are the basal ganglia. In fact, the highest levels of CB₁ receptors in the brain detected in autoradiography studies were found in the substantia nigra (Herkenham et al. 1991). In situ hybridization studies demonstrated that many striatal medium spiny neurons express CB₁ receptors (Matsuda et al. 1993; Julian et al. 2003). In contrast, adult pallidal and nigral neurons contain little or no CB₁ mRNA (Matsuda et al. 1993; Julian et al. 2003). Rather, CB₁ receptors in the globus pallidus and substantia nigra are localized to the axons traversing or terminating in these structures (Tsou et al. 1998a; Egertová and Elphick 2000). Thus, the high levels of pallidal and nigral CB₁ receptor binding and protein observed in autoradiographic and immunocytochemical studies mostly arise from GABAergic neurons projecting from the caudate putamen. Figure 8 illustrates the intense immunostaining of CB₁ receptors that begins at the border between the caudate putamen and globus pallidus. It is possible that dopaminergic neurons may transiently express CB₁ receptors during development, as CB₁ co-localizes with tyrosine hydroxylase in cultured mesencephalic neurons (Hernandez et al. 2000).

Both autoradiographic and immunocytochemical studies show a gradient of CB₁ expression in the rodent caudate putamen with the highest levels found dorsolaterally (Tsou et al. 1998a; Egertová and Elphick 2000). Both the matrix and patch structures of the caudate putamen contain CB₁ receptors, where they partially overlap with μ -opioid receptors (Rodriguez et al. 2001). CB₁ receptors are present on both the striatonigral (prodynorphin or preprotachykinin A positive) and striatopallidal (proenkephalin positive) projection pathways (Hohmann and Herkenham 2000). Thus, CB₁ receptors are positioned to modulate both the direct and indirect striatal output pathways.

In addition to medium spiny neurons, anatomical and functional studies identified CB₁ receptors on the terminals of the corticostriatal pathway (Gerdeman and Lovinger 2001; Huang et al. 2001; Rodriguez et al. 2001) and GABAergic aspiny interneurons (Hohmann and Herkenham 2000). In contrast, CB₁ receptors




Fig. 8A–C. CB₁ expression in basal ganglia detected by an antibody raised against the amino terminus of rat CB₁. **A** Low-power view showing moderate levels of CB₁ in caudate putamen (CPu) and very high levels in the globus pallidus (GP). The sharp demarcation between the two structures is evident. **B** Boundary of CPu and GP. Two moderately stained fiber bundles are indicated by the arrows. **C** High-power view of globus pallidus with fine, strongly immunoreactive, non-varicose processes corresponding to medium spiny neuron axons. Scale bars = 500 μ m (**A**); 50 μ m (**B** and **C**). (Modified from a photomicrograph provided by Kang Tsou)

do not appear to be expressed in the large aspiny cholinergic interneurons or somatostatin-containing interneurons (Hohmann and Herkenham 2000). CB₁ receptors are also present on the neurons in the subthalamic nucleus (Matsuda et al. 1993). Taken together, the presence of CB₁ receptors on diverse neuronal populations in the basal ganglia can account for the complex effects of cannabinoids on motor behaviors (Sanudo-Pena et al. 1999b; Romero et al. 2002).

2.5.3

Nucleus Accumbens

CB₁ receptors are also expressed at low to moderate levels in the nucleus accumbens. Here CB₁ receptors are found in a pattern reminiscent of the striatum. CB₁ receptors are expressed on terminals of the glutamatergic prefrontal cortex accumbens pathways (Robbe et al. 2001). They are also present on the accumbens medium spiny neurons. They appear to be absent from the dopaminergic terminals projecting to the accumbens from the ventral tegmentum. Consequently, cannabinoid stimulation of dopamine release in nucleus accumbens (Tanda et al. 1997) appears to be an indirect effect, perhaps mediated by inhibition of GABA release (Szabo et al. 1999, 2002).

2.5.4

Thalamus

Expression of CB₁ receptors in the thalamus is low (Herkenham et al. 1991; Jansen et al. 1992; Matsuda et al. 1993; Glass et al. 1997; Tsou et al. 1998a; Egertová and Elphick 2000). Regions of the thalamus with some CB₁ expression include the (lateral) habenular nucleus, the anterior dorsal thalamic nucleus, and the reticular thalamic nucleus (Herkenham et al. 1991; Mailleux and Vanderhaeghen 1992; Tsou et al. 1998a).

2.5.5

Hypothalamus

Given the marked effects of CB₁ receptor agonists on body temperature and antagonists on consumptive behavior, it is not surprising that CB₁ receptors are present in the hypothalamus. Low to moderate levels of CB₁ immunoreactivity are found in the paraventricular nucleus, ventral medial hypothalamic nucleus, infundibular stem, and lateral hypothalamic area (Tsou et al. 1998a). There are *in situ* data suggesting CB₁ receptors in the hypothalamus are primarily present on glutamatergic neurons (Marsicano and Lutz 1999). Intriguingly, although the levels of CB₁ receptors in hypothalamus are fairly low, functional studies with GTP γ S suggests these CB₁ receptors are more strongly coupled to G proteins than are most CB₁ receptors (Breivogel et al. 1997). A careful and detailed anatomical study of CB₁ expression in hypothalamus is needed because of the likely involvement of this region in the anti-appetitive actions of CB₁ antagonists.

2.6

Midbrain

2.6.1

Substantia Nigra

A striking feature of CB₁ receptor expression is the high number of CB₁ receptors found in the substantia nigra (Fig. 9A and 9B). As mentioned above, these receptors




Fig. 9A–C. CB₁ receptor expression in midbrain structures detected by an antibody against the amino terminus of rat CB₁. **A** CB₁ immunostaining is very strong in substantia nigra pars reticulata (SNR) but virtually absent in substantia nigra pars compacta (SNC). **B** Higher magnification view of SNR. When the plane of the section is perpendicular to the striatonigral pathway, immunoreactivity is apparent as puncta, from the high levels of axonal CB₁ expression. **C** In caudal periaqueductal gray, CB₁-positive fibers (arrows) and intensely labeled neuropil (arrowheads) are apparent. Aq, lumen of the aqueduct. Scale bars = 500 μ m (**A**), 50 μ m (**B**), and 20 μ m (**C**). (Modified from a photomicrograph provided by Kang Tsou)

appear to be restricted to the GABAergic axons of the putamen medium spiny neurons—the nigral dopaminergic neurons appear to be devoid of CB₁ receptors (Matsuda et al. 1993; Julian et al. 2003). Anatomical and functional evidence also suggests that the excitatory glutamatergic projection from the subthalamic nucleus to the substantia nigra contains CB₁ receptors (Mailleux and Vanderhaeghen 1992; Sanudo-Pena and Walker 1997; Sanudo-Pena et al. 1999b).

2.6.2

Ventral Tegmentum

CB₁ expression and function in the ventral tegmental area (VTA) is of interest because of the euphoric and reinforcing properties of cannabinoids—evident in carefully conducted studies. There is no evidence for CB₁ receptor expression on the tegmental dopamine neurons (Herkenham et al. 1991). Emerging functional evidence (detailed immunocytochemical studies remain to be done) suggests that CB₁ receptors are present on intrinsic GABAergic terminals, GABAergic terminals

present on accumbens neurons projecting to VTA, and glutamatergic terminals (Szabo et al. 2002; Riegel et al. 2003; Melis et al. 2004). These findings suggest that CB₁ receptor activation may play a role in the reinforcing effects of cannabinoids and, more provocatively, that disorders in endocannabinoid-mediated synaptic plasticity may be important in a broader range of addictive disorders.

2.6.3

Periaqueductal Gray

Moderate levels of CB₁ receptor are also found in several other regions of the mid-brain. One of these is the periaqueductal gray (PAG) (Fig. 9C). Here CB₁ receptors are found on the terminals of GABAergic neurons. In contrast to opiate receptors on GABAergic aqueductal neurons, CB₁ receptors are preferentially localized in the dorsal portion of the PAG (Tsou et al. 1998a). Autoradiographic studies indicate that CB₁ receptors are also found at moderate levels in the reticular formation and raphe nucleus (Glass et al. 1997).

2.7

Brainstem

Expression of CB₁ receptors in brainstem is relatively low. In contrast to the opioid receptors, few cannabinoid receptors are found in the medullary respiratory control centers (Herkenham et al. 1991; Glass et al. 1997). This likely underlies




Fig. 10. CB₁ expression in emetic centers. CB₁ is prominently expressed in the ferret area postrema (AP), dorsal vagal complex (DMNX), and associated regions involved in emesis as detected with a C-terminal CB₁ receptor antibody. Particularly strong immunostaining is present in a restricted group of cells in the area postrema as well as diffusely through the dorsal motor nucleus of the vagus (notice the lack of staining of cell bodies in DMNX), and the medial nucleus of the solitary tract (SolM). 4V, fourth ventricle; CC, central canal. Scale bar = 100 μ m. (Original photomicrograph provided by Marja Van Sickle and Keith Sharkey)

the low lethality of high doses of cannabinoids. One exception to the low levels of cannabinoid receptor in the brainstem is the medullary nuclei associated with emesis (Van Sickle et al. 2001). Here, as illustrated in Fig. 10, relatively high levels of CB₁ receptor are found in the dorsal motor nucleus of the vagus and the medial subnucleus of the nucleus of the solitary tract. Moderate levels are present in the subnucleus gelatinosus of the solitary tract (Fig. 10). Occasional, very strongly stained cells are evident in the area postrema (Fig. 10). In most cases, CB₁ receptors appear to be localized to terminal structures. Interestingly, FAAH immunoreactivity was restricted to the cell bodies invested by the CB₁-positive fibers (Van Sickle et al. 2001), continuing the theme of complementary expression of CB₁ receptors and FAAH. Compelling evidence suggests that a major portion of the antiemetic actions of cannabinoids is a consequence of CB₁ receptor activation in these nuclei (Van Sickle et al. 2001, 2003).

2.8 Cerebellum

CB₁ receptor expression in the cerebellum follows a striking and very predictable pattern. Autoradiographic and immunocytochemical studies show very strong labeling of the molecular layer (Fig. 11A), while in situ hybridization studies show robust expression in the granule cell layer (Matsuda et al. 1990; Herkenham et al. 1991; Glass et al. 1997; Tsou et al. 1998a; Egertová and Elphick 2000). Combining these results with functional studies suggests CB₁ receptors are expressed in climbing fibers and parallel fibers, as well as the basket cells, particularly at the basket cell–Purkinje cell synapse (Fig. 11A, B). In contrast, there is little evidence that Purkinje neurons express CB₁ receptors (Matsuda et al. 1990). Thus, both ma-




Fig. 11. CB₁ is highly expressed in the molecular layer and on the basket cell–Purkinje neuron synapse of the mouse cerebellum. **A** Using an antibody directed against the C terminus of the CB₁ receptor, strikingly high levels of CB₁ receptors are apparent at basket cell synapses onto the Purkinje neurons (*pc*) as well as diffusely high levels in the molecular layer (*mo*), corresponding to the parallel fiber–Purkinje neuron synapse. **B** Higher magnification view showing intense labeling of basket cell synapses (*arrowheads*), labeled fibers in the granule cell layer (*gr*) (*arrows*), and diffuse labeling in the molecular layer. Scale bars = 150 μm (**A**), and 15 μm (**B**). (Modified from a photomicrograph provided by Jane Lauckner)

for glutamatergic inputs and at least some of the GABAergic input onto Purkinje neurons are subject to modulation by cannabinoids. These anatomical observations are supported by several elegant electrophysiological studies demonstrating a role for endogenous cannabinoid inhibition of glutamatergic and GABAergic neurotransmission onto Purkinje neurons (Kreitzer and Regehr 2001; Maejima et al. 2001; Diana et al. 2002; Kreitzer et al. 2002; Brenowitz and Regehr 2003). While most of the actions of exogenous and endogenous cannabinoids can be interpreted as effects on presynaptic CB₁ receptors, there is also solid evidence for somatic expression of CB₁ receptors. This comes from experiments by the Regehr lab showing that the release of endocannabinoids from Purkinje neurons can slow the firing rate of basket cells, consistent with an activation of somatic potassium channels (Kreitzer et al. 2002).

2.9 Spinal Cord

Because of the efficacy of intrathecal cannabinoids in various pain models, it is not surprising that moderate levels of CB₁ receptor are found in the regions of the spinal cord associated with analgesia. In particular, the superficial layers of the dorsal horn, the dorsolateral funiculus, and lamina X all have moderate levels of CB₁ receptor (Farquhar-Smith et al. 2000). Cannabinoids inhibit glutamate release from afferents in lamina I of the dorsal horn in a CB₁ receptor-dependent fashion (Jennings et al. 2001; Morisset and Urban 2001). Providing anatomical support for these functional studies, CB₁ receptors are found in the dorsal horn in a characteristic twin band corresponding to lamina I and the inner portion of lamina II (Farquhar-Smith et al. 2000).

The source of CB₁ receptors in the dorsal horn remains controversial. One immunocytochemical study found little decrease in CB₁ receptor immunoreactivity following dorsal rhizotomy or hemisection of the spinal cord, suggesting CB₁ receptors are primarily expressed on interneurons (Farquhar-Smith et al. 2000). In contrast, another study using autoradiography to quantify CB₁ expression found a 50% decrease in CB₁ expression following dorsal rhizotomy, suggesting that approximately 50% of CB₁ receptors are found on primary afferents while the balance are on interneurons and descending pathways (Hohmann et al. 1999). Additional evidence supporting functionally significant levels of CB₁ expression on primary afferents includes the findings that CB₁ receptor activation inhibits glutamate release in lamina I (Jennings et al. 2001; Morisset and Urban 2001), only low levels of CB₁ mRNA are present in spinal cord (Mailleux and Vanderhaeghen 1992), and CB₁ receptor mRNA and protein are both expressed in dorsal root ganglia cells (Hohmann et al. 1999; Hohmann and Herkenham 1999b; Bridges et al. 2003). Despite the presence of CB₁ receptors on some C fibers, many more are present on large, myelinated fibers (Abeta and Adelta) (Hohmann and Herkenham 1998, 1999b; Bridges et al. 2003; Price et al. 2003). In balance, it is likely that the analgesic effects of CB₁ receptor activation in the spinal cord are due to interplay between cannabinoid actions on primary afferents, interneurons, and descending pathways.

Emerging evidence suggests that CB₂ agonists are analgesic in a number of neuropathic and inflammatory pain models (Ibrahim et al. 2003; Nackley et al. 2003; Hohmann et al. 2004). There is little evidence for CB₂ expression in normal spinal cord (for example, Buckley et al. 1998). However, CB₂ expression is induced in the spinal cord, likely in microglial cells, following nerve injury and the development of a neuropathic state (Zhang et al. 2003). Precise localization of these receptors using immunocytochemistry remains to be performed. Intriguingly, CB₂ receptor expression was not increased in an inflammatory pain model, despite the efficacy of CB₂ agonists as analgesics in this model. This suggests that CB₂ receptors are selectively upregulated only after specific forms of nerve injury. It also implies that peripheral CB₂ receptors mediate some of the effects of CB₂ agonists, at least some inflammatory pain states.

While expression of CB₁ in the dorsal horn is well established, its expression in spinal cord areas associated with movement is less certain. However, some immunocytochemical evidence suggests CB₁ receptors are found in the ventral horn (Tsou et al. 1998a; Sanudo-Pena et al. 1999a). Interestingly, FAAH is also found in the cell bodies of ventral horn neurons (Tsou et al. 1998b). The localization of CB₁ receptors and FAAH in neuronal circuits associated with movement may underlie the antispastic effects of cannabinoids.

3

Peripheral Nervous System

3.1

Peripheral Nerves

There is strong evidence for CB₁ receptor expression in the periphery. For example, ligation of the sciatic nerve leads to accumulation of CB₁ receptors proximal to the ligation (Hohmann and Herkenham 1999a) and peripherally administered, but systemically inactive, doses of CB₁ agonists can be analgesic (Calignano et al. 1998). To date, no studies have been published examining CB₁ receptors in the periphery beyond major nerves (e.g., sciatic). The development of sufficiently sensitive techniques to study CB₁ and CB₂ expression in the periphery is needed to thoroughly understand the peripheral actions of these compounds. Cannabinoids also regulate autonomic nervous system function. Examples include cannabinoid inhibition of neurotransmitter release in ileum (Roth 1978; Pertwee et al. 1992; Croci et al. 1998) and vas deferens (Nicolau et al. 1978; Pertwee et al. 1992).

3.2

Enteric Nervous System

CB₁ receptors are richly distributed throughout the enteric nervous system; their function has been the focus of reviews (Pertwee 2001; Pinto et al. 2002). Cannabis and its psychoactive extracts inhibit intestinal motility (Shook and Burks 1989; Izzo

et al. 1999). Detailed anatomical studies have found high levels of CB₁ receptor in specific populations of nerves innervating the gut (Kulkarni-Narla and Brown 2000; Coutts et al. 2002; MacNaughton et al. 2004). Studies of guinea pig ileum suggest that CB₁ receptors are localized, in part to the cholinergic myenteric motor neurons (Coutts et al. 2002). Activation of these presynaptic CB₁ receptors inhibits acetylcholine release, decreasing longitudinal muscle contractions. Intestinal motility mediated by non-adrenergic, non-cholinergic (NANC) neurotransmission is also decreased by CB₁ agonists (Izzo et al. 1998); likewise, CB₁ receptors are also found on some NANC neurons (MacNaughton et al. 2004). Activation of CB₁ receptors also decreases fluid secretion in the stomach and intestine. Consistent with this, CB₁ receptors are present in both cholinergic and non-cholinergic sensorimotor submucosal neurons (Tyler et al. 2000; Adami et al. 2002; MacNaughton et al. 2004). CB₁ receptors are also present on some vagal afferents, where their expression is decreased by food intake and CCK (Burdyga et al. 2004).

3.3

Pelvic Viscera

Several studies suggest CB₁ receptor activation has effects on bladder, vas deferens, and uterine function, in both normal and pathophysiological states (Nicolau et al. 1978; Pertwee et al. 1992; Pertwee and Fernando 1996; Dmitrieva and Berkley 2002; Farquhar-Smith et al. 2002). While CB₁ receptors are expressed on tyrosine hydroxylase (noradrenaline)-positive pelvic neurons (Pan et al. 1998), detailed studies on CB₁ receptor distribution to these organs remains to be performed.

4

Summary

The pattern of CB₁ expression in the brain generally correlates with its function both at the macroscopic and microscopic levels. High levels of cannabinoid receptors are found in brain regions implicated in the behavioral effects of cannabinoids, particularly cortex, hippocampus, amygdala, basal ganglia, cerebellum, and the emetic centers of the brainstem. Conversely, low levels are found in other regions, such as the thalamus, pons, and the remainder of the brainstem. Correspondingly, these areas have generally not been implicated in playing a major role in the actions of cannabis or cannabinoids. Undoubtedly, the future will bring further refinement in the localization of CB₁ receptors as well as the badly needed details on where endocannabinoid synthesizing and degrading enzymes are found. Together, this information will aid in our understanding of the role of CB₁ receptors in the function of the CNS, both in normal physiology as well as in pathological states.

Acknowledgements. I would like to dedicate this review to the memory of Professor Kang Tsou, who first introduced me to the intricacies, beauty, and logic of CB₁ immunocytochemistry in the CNS. I am indebted to my collaborators and colleagues who have provided

images to use as figures in this review: Tibor Harkany, Tamas Freund and Agnes Bodor, Kang Tsou, Marja Van Sickle and Keith Sharkey, Miles Herkenham, and Jane Lauckner. In addition, I am grateful to these individuals and many others for stimulating discussions on the insight that CB₁ receptor localization gives us to understand the role of endogenous and exogenous cannabinoids in CNS function. The writing of this chapter has been supported in part by grants from the NIH, DA00286 and DA11322.

References

- Adami M, Frati P, Bertini S, Kulkarni-Narla A, Brown DR, de Caro G, Coruzzi G, Soldani G (2002) Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. *Br J Pharmacol* 135:1598–1606
- Beinfeld MC, Connolly K (2001) Activation of CB₁ cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. *Neurosci Lett* 301:69–71
- Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* 163:463–468
- Breivogel CS, Sim LJ, Childers SR (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. *J Pharmacol Exp Ther* 282:1632–1642
- Brenowitz SD, Regehr WG (2003) Calcium dependence of retrograde inhibition by endocannabinoids at synapses onto Purkinje cells. *J Neurosci* 23:6373–6384
- Bridges D, Rice AS, Egertová M, Elphick MR, Winter J, Michael GJ (2003) Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. *Neuroscience* 119:803–812
- Buckley NE, Hansson S, Harta G, Mezey E (1998) Expression of the CB₁ and CB₂ receptor messenger RNAs during embryonic development in the rat. *Neuroscience* 82:1131–1149
- Burdys G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ (2004) Expression of cannabinoid CB₁ receptors by vagal afferent neurons is inhibited by cholecystokinin. *J Neurosci* 24:2708–2715
- Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. *Nature* 394:277–281
- Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M, Dinh TP, Piomelli D, Mackie K, Soltesz I (2003) Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. *Neuron* 39:599–611
- Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S (2002) Localisation of cannabinoid CB₁ receptor immunoreactivity in the guinea pig and rat myenteric plexus. *J Comp Neurol* 448:410–422
- Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, Ferla G (1998) In vitro functional evidence of neuronal cannabinoid CB₁ receptors in human ileum. *Br J Pharmacol* 125:1393–1395
- Diana MA, Levenes C, Mackie K, Marty A (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. *J Neurosci* 22:200–208
- Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci U S A* 99:10819–10824
- Dmitrieva N, Berkley KJ (2002) Contrasting effects of WIN 55212–2 on motility of the rat bladder and uterus. *J Neurosci* 22:7147–7153

- Egertová M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. *J Comp Neurol* 422:159–171
- Egertová M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. *Proc R Soc Lond B Biol Sci* 265:2081–2085
- Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. *Neuroscience* 119:481–496
- Farquhar-Smith WP, Egertová M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR (2000) Cannabinoid CB(1) receptor expression in rat spinal cord. *Mol Cell Neurosci* 15:510–521
- Farquhar-Smith WP, Jaggar SI, Rice AS (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. *Pain* 97:11–21
- Freund TF (2003) Interneuron diversity series: rhythm and mood in perisomatic inhibition. *Trends Neurosci* 26:489–495
- Freund TF, Buzsáki G (1996) Interneurons of the hippocampus. *Hippocampus* 6:347–470
- Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev* 83:1017–1066
- Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. *J Neurophysiol* 85:468–471
- Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience* 77:299–318
- Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum, and amygdala. *Eur J Neurosci* 20:441–458
- Hajos N, Freund TF (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. *Neuropharmacology* 43:503–510
- Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. *Eur J Neurosci* 12:3239–3249
- Hajos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. *Neuroscience* 106:1–4
- Harkany T, Hartig W, Berghuis P, Dobszay MB, Zilberter Y, Edwards RH, Mackie K, Ernfor P (2003) Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons. *Eur J Neurosci* 18:1979–1992
- Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci* 11:563–583
- Hernandez M, Berrendero F, Suarez I, Garcia-Gil L, Cebeira M, Mackie K, Ramos JA, Fernandez-Ruiz J (2000) Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. *Brain Res* 857:56–65
- Hohmann AG, Herkenham M (1998) Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. *Neurosci Lett* 252:13–16
- Hohmann AG, Herkenham M (1999a) Cannabinoid receptors undergo axonal flow in sensory nerves. *Neuroscience* 92:1171–1175
- Hohmann AG, Herkenham M (1999b) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. *Neuroscience* 90:923–931
- Hohmann AG, Herkenham M (2000) Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. *Synapse* 37:71–80

- Hohmann AG, Briley EM, Herkenham M (1999) Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. *Brain Res* 822:17–25
- Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004) Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. *J Pharmacol Exp Ther* 308:446–453
- Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. *J Physiol* 532:731–748
- Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. *Proc Natl Acad Sci U S A* 100:10529–10533
- Izzo AA, Mascolo N, Borrelli F, Capasso F (1998) Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. *Br J Pharmacol* 124:1363–1368
- Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F (1999) The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. *Eur J Pharmacol* 384:37–42
- Jansen EM, Haycock DA, Ward SJ, Seybold VS (1992) Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. *Brain Res* 575:93–102
- Jennings EA, Vaughan CW, Christie MJ (2001) Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. *J Physiol* 534:805–812
- Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, Garcia-Segura LM (2003) Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. *Neuroscience* 119:309–318
- Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. *J Neurosci* 19:4544–4558
- Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirkak S, Mackie K, Vizi ES, Freund TF (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. *Neuroscience* 100:797–804
- Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. *J Neurosci* 21:9506–9518
- Kirby MT, Hampson RE, Deadwyler SA (1995) Cannabinoids selectively decrease paired-pulse facilitation of perforant path synaptic potentials in the dentate gyrus in vitro. *Brain Res* 688:114–120
- Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. *Neuron* 29:717–727
- Kreitzer AC, Carter AG, Regehr WG (2002) Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. *Neuron* 34:787–796
- Kulkarni-Narla A, Brown DR (2000) Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. *Cell Tissue Res* 302:73–80
- Lu XR, Ong WY, Mackie K (1999) A light and electron microscopic study of the CB1 cannabinoid receptor in monkey basal forebrain. *J Neurocytol* 28:1045–1051
- Lutz B (2002) Molecular biology of cannabinoid receptors. *Prostaglandins Leukot Essent Fatty Acids* 66:123–142
- MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA (2004) Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. *Am J Physiol Gastrointest Liver Physiol* 286:G863–G871
- Maejima T, Ohno-Shosaku T, Kano M (2001) Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. *Neurosci Res* 40:205–210

- Mailleux P, Vanderhaeghen JJ (1992) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. *Neuroscience* 48:655–668
- Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. *Eur J Neurosci* 11:4213–4225
- Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. *Nature* 418:530–534
- Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. *Science* 302:84–88
- Mato S, Del Olmo E, Pazos A (2003) Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. *Eur J Neurosci* 17:1747–1754
- Matsuda LA (1997) Molecular aspects of cannabinoid receptors. *Crit Rev Neurobiol* 11:143–166
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 346:561–564
- Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. *J Comp Neurol* 327:535–550
- McDonald AJ, Mascagni F (2001) Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. *Neuroscience* 107:641–652
- Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. *J Neurosci* 24:53–62
- Morales M, Wang SD, Diaz-Ruiz O, Jho DH (2004) Cannabinoid CB1 receptor and serotonin 3 receptor subunit A (5-HT3A) are co-expressed in GABA neurons in the rat telencephalon. *J Comp Neurol* 468:205–216
- Morisset V, Urban L (2001) Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. *J Neurophysiol* 86:40–48
- Morozov YM, Freund TF (2003) Post-natal development of type 1 cannabinoid receptor immunoreactivity in the rat hippocampus. *Eur J Neurosci* 18:1213–1222
- Nackley AG, Makriyannis A, Hohmann AG (2003) Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. *Neuroscience* 119:747–757
- Nicolau M, Lapa AJ, Valle JR (1978) The inhibitory effect induced by delta9-tetrahydrocannabinol on the contractions of the isolated rat vas deferens. *Arch Int Pharmacodyn Ther* 236:131–136
- Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. *J Biol Chem* 279:5298–5305
- Pan X, Ikeda SR, Lewis DL (1998) SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca²⁺ currents by reversal of tonic CB1 cannabinoid receptor activity. *Mol Pharmacol* 54:1064–1072
- Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. *Gut* 48:859–867
- Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. *Br J Pharmacol* 118:2053–2058
- Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. *Br J Pharmacol* 105:980–984
- Pinto L, Capasso R, Di Carlo G, Izzo AA (2002) Endocannabinoids and the gut. *Prostaglandins Leukot Essent Fatty Acids* 66:333–341

- Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003) The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. *Neuroscience* 120:155–162
- Riegal AC, Williams JT, Lupica CR (2003) Cannabinoid CB1 receptors inhibit GABA-B-mediated synaptic currents in midbrain dopaminergic neurons. *Soc Neurosci Abstr* 33:462466
- Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. *J Neurosci* 21:109–116
- Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. *J Neurosci* 21:823–833
- Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J (2002) The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. *Pharmacol Ther* 95:137–152
- Roth SH (1978) Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. *Can J Physiol Pharmacol* 56:968–975
- Sanudo-Pena MC, Walker JM (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. *J Neurophysiol* 77:1635–1638
- Sanudo-Pena MC, Strangman NM, Mackie K, Walker JM, Tsou K (1999a) CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. *Zhongguo Yao Li Xue Bao* 20:1115–1120
- Sanudo-Pena MC, Tsou K, Walker JM (1999b) Motor actions of cannabinoids in the basal ganglia output nuclei. *Life Sci* 65:703–713
- Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. *J Biol Chem* 270:3726–3731
- Shook JE, Burks TF (1989) Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. *J Pharmacol Exp Ther* 249:444–449
- Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996a) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. *J Neurosci* 16:8057–8066
- Sim LJ, Selley DE, Xiao R, Childers SR (1996b) Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. *Eur J Pharmacol* 307:97–105
- Sjostrom PJ, Turrigiano GG, Nelson SB (2003) Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. *Neuron* 39:641–654
- Szabo B, Muller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. *J Neurochem* 73:1084–1089
- Szabo B, Siemes S, Wallmichrath I (2002) Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. *Eur J Neurosci* 15:2057–2061
- Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. *Science* 276:2048–2050
- Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998a) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. *Neuroscience* 83:393–411
- Tsou K, Nogueron MI, Muthian S, Sanudo-Pena MC, Hillard CJ, Deutsch DG, Walker JM (1998b) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. *Neurosci Lett* 254:137–140
- Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. *Neuroscience* 93:969–975

- Tyler K, Hillard CJ, Greenwood-Van Meerveld B (2000) Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. *Eur J Pharmacol* 409:207–211
- Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. *Gastroenterology* 121:767–774
- Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. *Am J Physiol Gastrointest Liver Physiol* 285:G566–G576
- Wilson RI, Kunos G, Nicoll RA (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. *Neuron* 31:453–462
- Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. *Eur J Neurosci* 17:2750–2754